First Ever Biosimilar Approval in China: Trouble for Roche?
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats…
Address: 27 Chao Qian Road,
Changping District Beijing, 102200, China
Tel: -69722764
Web: http://www.zhongsheng.com.cn/en/index.asp
BioSino Bio-technology and Science Inc, founded in 1988, is a leading high-technology enterprise whose major national controlling stakeholders comprise the Chinese Academy of Sciences, Beijing Municipal Government and Shanghai Municipal Government. Biosino has already become the largest manufacturer of IVD reagents in China after 20 years development.BioSino successfully finished IPO in GEM of Hong Kong Stock in 2006, symbolizing that she has marched away for her globalization, grouping and synthesis of running both products and capital. Now, Biosino has 90 IVD products, more than 200 formats including biochemistry diagnostic reagents, immunology diagnostic reagents and rapid tests. Lots of our products have got CE mark and more products are in the process of application. Now, BioSino has developed over 600 distributors and retailers over the country, occupy 75% of the Chinese market. Moreover, we have exported to over 20 countries from Southeast Asia, Middle-east, North Africa, and South America.In order to ensure consistently high quality, BioSino built a new GMP standard plant (11000m2) and established a microcomputer-controlled automated production line to achieve a completely sealed, sterile, temperature and humidity controlled environment. At the same time, meticulous and experienced employees are hired for quality control, technological safeguards and production operations. Each step is strictly in accordance with the requirements of quality control standards ISO9001:2000 and ISO13485:2003.BioSino has a professional after sales service team comprising experts in the field of biochemistry, immunology, pharmacy and medicine. We provide on-the-spot technological support and service to our customers, teach them how to use our products and resolve problems they meet. Our commitment is to provide the best service at the first moment.Looking into the future, BioSino will keep on developing new products to meet the demands of international markets. Our aim is to become a leading diagnostic manufacturer in the world and create a better future together with our partners and customers.
Bio Chemistry Reagents
Immunology Reagents
Rapid Testing Diagnostics
Diagnostic Instruments
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats…
The lowdown on what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Robert Hall of Ardent Search outlines…
George Lee, vice-president of clinical operations and country leader of PAREXEL in China, discusses the impact of the recent ownership and management changes of the group, the value that PAREXEL…
One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, the cardiology treatment, Neucardin®. With…
It has been announced by China’s State Council that as of March 1st 2019, the government will reduce the VAT on a “first batch” of 21 rare disease drugs and four…
This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging…
Terns Pharmaceuticals is developing innovative drugs for the treatment of NASH and liver disease. It has established a diverse product pipeline with drug candidates targeting different stages of the disease…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the…
Brian Mi, president of IQVIA Greater China, shares IQVIA’s leadership position in China in both the commercial and R&D space, building on both IMS Health and Quintiles’ market positioning in…
Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved…
Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein…
Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative…
See our Cookie Privacy Policy Here
